Evidence map›Paper›PMID 41911451›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Cytotoxic T cell recognition of α-synuclein drives pathogenic immune responses in multiple system atrophy.

Jae-Seung Moon, Salvinaz I Moutusy, Mengrui Zhang, Alain Ndayisaba, Diego Rodriguez, Daniel N El Kodsi, Anastasia Kuzkina, Shady Younis, Shaghayegh Jahanbani, Laura S van Dam and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Cytotoxic T cell recognition of α-synuclein drives pathogenic immune responses in multiple system atrophy.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jae-Seung Moon *Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA 94305.
Salvinaz I Moutusy *Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA 94305.
Mengrui ZhangDivision of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA 94305.
Alain NdayisabaDivision of Movement Disorders Harvard Biomarkers Study 2.0 (HBS 2.0) and MyTrial Programs, American Parkinson Disease Association, Center for Advanced Research and MSA Center of Excellence, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's and Massachusetts General Hospitals (Mass General Brigham), Boston, MA 02115.ORCID 0000-0001-7611-7115
Diego RodriguezDivision of Movement Disorders Harvard Biomarkers Study 2.0 (HBS 2.0) and MyTrial Programs, American Parkinson Disease Association, Center for Advanced Research and MSA Center of Excellence, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's and Massachusetts General Hospitals (Mass General Brigham), Boston, MA 02115.
Daniel N El KodsiDivision of Movement Disorders Harvard Biomarkers Study 2.0 (HBS 2.0) and MyTrial Programs, American Parkinson Disease Association, Center for Advanced Research and MSA Center of Excellence, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's and Massachusetts General Hospitals (Mass General Brigham), Boston, MA 02115.
Anastasia KuzkinaDivision of Movement Disorders Harvard Biomarkers Study 2.0 (HBS 2.0) and MyTrial Programs, American Parkinson Disease Association, Center for Advanced Research and MSA Center of Excellence, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's and Massachusetts General Hospitals (Mass General Brigham), Boston, MA 02115.ORCID 0000-0001-5443-8540
Shady YounisDivision of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA 94305.ORCID 0000-0002-4319-1738
Shaghayegh JahanbaniDivision of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA 94305.
Laura S van DamDivision of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA 94305.
Ya'el CourtneyDivision of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA 94305.
Adi NetanelVA Palo Alto Health Care System, Palo Alto, CA 94304.
Orr SharpeDivision of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA 94305.
Mitchell G MiglisDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305.
Lawrence SteinmanDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305.ORCID 0000-0002-2437-2250
Vikram KhuranaDivision of Movement Disorders Harvard Biomarkers Study 2.0 (HBS 2.0) and MyTrial Programs, American Parkinson Disease Association, Center for Advanced Research and MSA Center of Excellence, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's and Massachusetts General Hospitals (Mass General Brigham), Boston, MA 02115.
Fereshteh JahanbaniDivision of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA 94305.
William H RobinsonDivision of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA 94305.ORCID 0000-0003-4385-704X

Funding

Investigating Mucosal Breaks in the Initiation and Progression of Rheumatoid ArthritisR01AR078268 · NIAMS · STANFORD UNIVERSITY · PI ORANGE, DANA ELIZABETH, ROBINSON, WILLIAM H · 2021 to 2025
$3.1M
Deciphering the Role of Epstein-Barr Virus Molecular Mimicry and B cell Transformation in Multiple SclerosisR01AI173189 · NIAID · STANFORD UNIVERSITY · PI Tobias Volker Lanz, William H Robinson · 2023 to 2026
$2.3M
Brennan Family 01HHS | National Institutes of Health (NIH) AI173189-01HHS | National Institutes of Health (NIH) PATHO-PH2-SUB_17_23HHS | National Institutes of Health (NIH) R01AR078268Mission MSA CURE-MSA 01NIAID NIH HHS R01 AI173189NIAMS NIH HHS R01 AR078268
6 · The paper itself

Abstract

Multiple system atrophy (MSA) is a progressive neurologic disease, known as an α-synucleinopathy. There are currently no effective disease-modifying therapies for MSA. While neuroinflammation is a hallmark of MSA, the contribution of adaptive immune mechanisms remains poorly understood. Here, we profiled peripheral and central T cell responses in patients with MSA, in comparison with Parkinson's disease (PD) and healthy control cohorts, using single-cell transcriptomics, flow cytometry, and antigen-specific functional assays. We demonstrated that peripheral T cells from MSA patients are activated and skewed toward cytotoxic and inflammatory phenotypes. Single-cell transcriptomics further revealed clonal expansion of cytotoxic CD8

Indexed as

alpha-SynucleinMultiple System AtrophyT-Lymphocytes, CytotoxicAgedBrainCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansMaleMiddle AgedParkinson Diseasealpha-Synucleinantigen-specific T cell responsescytotoxic T cellsmultiple system atrophyneuroinflammationα-synuclein

Identifiers

PMID41911451
PMCPMC13056084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.